Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

Launched by I-LUMEN SCIENTIFIC, INC. · Jul 1, 2022

Keywords

ClinConnect Summary

The i-SIGHT clinical trial is studying a treatment called microcurrent stimulation therapy for people with a specific type of eye condition known as nonexudative age-related macular degeneration (AMD), often referred to as dry AMD. This condition can lead to vision problems as we age, but the trial is focused on seeing if this therapy can help improve safety and effectiveness for those affected. The trial is currently active but not recruiting new participants.

To be eligible for this trial, participants need to be at least 50 years old and have been diagnosed with a specific stage of dry AMD. They should have some vision loss but still be able to see well enough in one eye. However, people with certain other eye conditions, a history of smoking, or other specific health issues cannot participate. If someone joins the trial, they can expect to receive the microcurrent therapy and be closely monitored for its effects on their vision. This study aims to find out if this new therapy can make a difference in managing their condition.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Age ≥50 years.
• • Non-exudative age-related macular degeneration defined as AREDS category 3 Intermediate AMD and/or geographic atrophy
• • Best-corrected distance visual acuity 20/40 to 20/200 (inclusive) in the study eye, and BCVA 20/100 or better in the fellow eye
• Key Exclusion Criteria:
• • History and/or evidence of exudative age-related macular degeneration in either eye
• • History and/or evidence of diabetic retinopathy in either eye
• • Current tobacco or tobacco-related product use or history within the past 10 years of heavy smoking (on average, more than half a pack of cigarettes per day)
• • Central chorioretinal atrophy in the study eye
• • Glaucoma in the study eye